Fengzhi Li
8PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Mar 13, 2025
Targeted Treatment of Sarcomas by Single Protein Encapsulated Doxorubicin with Undetectable Cardiotoxicity and Superior Efficacy.Changjun Yu, Faqing Huang, Leslie Wang
|Aug 18, 2023
Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence.Fengzhi Li, Xiang Ling, Sayan Chakraborty
|Jun 24, 2022
Investigation of the Uptake and Transport of Two Novel Camptothecin Derivatives in Caco-2 Cell Monolayers.Yi Wang, Xiangli Zhang, Wenya Zhuang
|Jun 10, 2022
Molecular Glues: Capable Protein-Binding Small Molecules That Can Change Protein-Protein Interactions and Interactomes for the Potential Treatment of Human Cancer and Neurodegenerative Diseases.Fengzhi Li, Ieman A M Aljahdali, Xiang Ling
|May 23, 2022
FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy.Xiang Ling, Wenjie Wu, Ieman A M Aljahdali
|Aug 13, 2021
Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.Fengzhi Li, Ieman A M Aljahdali, Renyuan Zhang
Pageof 2
